“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !

Anavex said that the candidate's safety profile also appeared to be relatively good.

Anavex also better in ADAS-Cog14, and far superior safety profile.

>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!

$AVXL safety profile = excellent !!

with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.

$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.

"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”

Safety profile is decent.

Appears to have a clean safety profile.

But what made me invest and hold through the turbulence was watching Simu's safety profile & performance trend further develop at each trial update--peerless and unassailable.

These clinical data combined with a clean safety profile and easy oral administration suggest highly encouraging and durable treatment effects for people living with Alzheimer’s disease.”

Simufilam boosts soluble level of Amyloid bera42 which in turn improves or maintains cognition in Alz patients This, along with its superior safety profile, will win the approval undoubtedly!